ETF1

Across TCGA pan-cancer cohorts, ETF1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ETF1 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ETF1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ETF1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where ETF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.637	1.000	.003	17	view →
LUAD	DFS	Tertile	All	0.532	0.957	.001	11	view →
GBM	DFS	Tertile	All	0.644	0.826	.009	9	view →
HNSC	DFS	Quartile	III,IV	0.864	0.597	.013	6	view →
PDAC	DFS	Median	IV	0.245	0.766	.017	6	view →
LSCC	DFS	Median	III,IV	0.433	0.900	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ETF1–CCRCC (OS)

Open the CCRCC breakdown →